Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Conferences 2021

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Francesca Bruce

Senior Reporter Pharma Insights

About Francesca

USA

+13 year(s) experience

Francesca has been writing news and analysis relating to the pharmaceutical industry since 2008, paying special attention to market access developments across the world. Francesca regularly speaks to a range of stakeholders from across the sector to bring readers insights on key developments.

Francesca writes about a broad range of policy and regulatory topics, including intellectual property rights. However, her main areas of expertise are pricing and reimbursement and how medicines may or may not make it to patients. She writes about developments in Europe but is also expanding coverage in emerging markets, including Latin America and the Middle East. Francesca writes for Scrip, Pink Sheet and In Vivo.

Specialties

Policy & Regulation
Market Access
Pricing & Reimbursement

Francesca writes For

Pink Sheet

COVID-19 Causes Further Delay To Canada’s Controversial Pricing Reforms

A delay to implementing drug pricing reforms is an opportunity for Canadian authorities to come up with better proposals, say industry representatives, while authorities remain adamant that action is necessary to lower prices.

View article
Pink Sheet

How Sustainable Is England's Cancer Drugs Fund?

The Cancer Drugs Fund has improved access to oncology drugs, but if it is to remain fit for purpose it will need to evolve.

Topic Cancer

View article
Pink Sheet

Brexit Issues Lead NICE To Delay Methods Review

England’s health technology appraisal body, NICE, and the UK medicines regulator, the MHRA, are working together to align their process timelines so that access to medicines is “maintained and enhanced.”

Topic Brexit Pharma-Brexit EU

View article
Pink Sheet

Germany Sets Direction Of Travel With New Biosimilar Guidelines

Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in move towards increasing biosimilar uptake.

Topic EU Biosimilars

View article
Pink Sheet

Long-Awaited Brexit White Paper Lays Out UK’s Plans For Medicines Regulation

The UK government has finally published its white paper on the UK’s future relationship with the EU following Brexit, to the relief of the pharmaceutical industry.

Topic Pharma-Brexit Brexit Regulation EU

View article
Pink Sheet

Canada: National Pharmacare Or 'Fill The Gaps'?

A national pharmacare program in Canada could make it harder to access higher cost drugs.

Topic Policy and regulation

View article
Pink Sheet

Lessons From Mercosur Multi-Country Pricing Negotiations

Latin American joint price negotiations have proved successful and other countries are taking note.

Topic Business strategies Deal trends

View article
Pink Sheet

Latin America Inches Towards Greater Regulatory Harmonization

Regulatory harmonization is gathering pace in Latin America, which is good news for pharmaceutical companies.

Topic Policy and regulation

View article
Pink Sheet

UK Industry Raises Conflict of Interest Concerns Over NICE’s PRIMA Service

PRIMA, the new service the National Institute for Health and Care Excellence offers to review economic models, must not be affected by confidentiality and conflict of interest issues, warns UK the pharmaceutical industry group, ABPI.

Topic Business strategies

View article
Pink Sheet

Long-Awaited Brexit White Paper Lays Out UK's Plans For Medicines Regulation

The UK government has finally published its white paper on the UK’s future relationship with the EU following Brexit, to the relief of the pharmaceutical industry.

Topic Brexit

View article
Pink Sheet

EU Under Fire Again For Pursuing Investor-State Dispute Settlement-like Mechanisms

The EU is once again facing criticism for its pursuit of investor-state dispute settlement-like mechanisms.

View article
Pink Sheet

AstraZeneca On Bridging The Gap Between Accelerated Approval And HTA Requirements

Health technology assessment agencies are struggling to evaluate drugs on the basis of evidence generated for early approvals.

Topic BioPharmaceutical

View article
Scrip

Lost $700m Opportunity As PTC Bids Farewell to Translarna in CF

In withdrawing its European marketing application for Translarna in cystic fibrosis, PTC Therapeutics has bid farewell to a market opportunity once pegged at $700m.

View article